Open Access Articles- Top Results for Delavirdine


File:Delavirdine ball-and-stick.png
Systematic (IUPAC) name
Clinical data
Trade names Rescriptor
AHFS/ monograph
MedlinePlus a600034
  • AU: B3
  • US: C (Risk not ruled out)
Pharmacokinetic data
Bioavailability 85%
Protein binding 98%
Metabolism Hepatic (CYP3A4- and CYP2D6-mediated)
Half-life 5.8 hours
Excretion Renal (51%) and fecal (44%)
136817-59-9 7pxY
PubChem CID 5625
DrugBank DB00705 7pxY
ChemSpider 5423 7pxY
KEGG D07782 7pxY
ChEBI CHEBI:119573 7pxY
NIAID ChemDB 005059
Chemical data
Formula C22H28N6O3S
456.562 g/mol
 14pxY (what is this?)  (verify)

Delavirdine (DLV) (brand name Rescriptor) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by ViiV Healthcare. It is used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1. It is presented as the mesylate. The recommended dosage is 400 mg, three times a day.

Although delavirdine was approved by the U.S. Food and Drug Administration in 1997, its efficacy is lower than other NNRTIs, especially efavirenz, and it also has an inconvenient schedule. These factors have led the U.S. DHHS not to recommend its use as part of initial therapy.[1] The risk of cross-resistance across the NNRTI class, as well as its complex set of drug interactions, make the place of delavirdine in second-line and salvage therapy unclear, and it is currently rarely used.


Like ritonavir, delavirdine is an inhibitor of cytochrome P450 isozyme CYP3A4, and interacts with many medications. It should not be administered with a wide range of drugs, including amprenavir, fosamprenavir, simvastatin, lovastatin, rifampin, rifabutin, rifapentine, St John's wort, astemizole, midazolam, triazolam, ergot medications, and several medications for acid reflux.[1]

Adverse effects

The most common adverse event is moderate to severe rash, which occurs in up to 20% of patients.[2] Other common adverse events include fatigue, headache and nausea. Liver toxicity has also been reported.

External links


  1. ^ a b DHHS panel. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 4, 2006). (Available for download from AIDSInfo)
  2. ^ RESCRIPTOR brand of delavirdine mesylate tablets. Product information.